Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

vobramitamab duocarmazine (MGC018) - MacroGenics

A-1331852 - AbbVie

http://www.ncbi.nlm.nih.gov/pubmed/42348027

Canan D Dirican; Colm Morrissey; Galina Semenova; Ilsa Coleman; Jessica Maruwan; John K Lee; Michael C Haffner; Peter S Nelson; Roman Gulati; Ruth Dumpit; Sander B Frank; Tarana Arman; Wanting Han

Jun 26, 2026